-5%
Xofyl 400 mg is a novel methylxanthine bronchodilator that differs structurally from theophylline by the inclusion of a dioxolane group at position 7. It selectively inhibits PDE-4, leading to bronchial smooth muscle relaxation. Reduced interaction with adenosine A₁ and A₂ receptors contributes to improved tolerability. Inhibition of PAF and leukotriene production further enhances its therapeutic effect.
Xofyl 400 mg is a newer-generation bronchodilator that is structurally distinct from theophylline due to the presence of a dioxolane group at position 7. It exerts its bronchodilatory effect primarily through selective inhibition of phosphodiesterase-4 (PDE-4), leading to relaxation of bronchial smooth muscle.
Unlike theophylline, Xofyl demonstrates reduced affinity for adenosine A₁ and A₂ receptors, which may explain its comparatively improved safety and tolerability profile. Additionally, Xofyl has been reported to inhibit platelet-activating factor (PAF) and suppress leukotriene synthesis, contributing to its anti-inflammatory and bronchodilatory actions.
Overdose may result in serious adverse reactions, including:
- Severe cardiac arrhythmias
- Tonic–clonic seizures
These may be the initial signs of toxicity. Treatment should be discontinued if adverse effects occur and may be resumed at lower doses after symptoms resolve, at the physician’s discretion. There is no specific antidote; management is supportive and symptomatic, particularly in cases of cardiovascular compromise.